Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBT: 2020-2025

Historic EBT for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$52.8 million.

  • Rhythm Pharmaceuticals' EBT fell 20.03% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.9 million, marking a year-over-year increase of 25.70%. This contributed to the annual value of -$260.3 million for FY2024, which is 41.36% down from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' EBT stood at -$52.8 million, which was down 14.04% from -$46.3 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year EBT high stood at $65.8 million for Q1 2021, and its period low was -$141.1 million during Q1 2024.
  • Moreover, its 3-year median value for EBT was -$46.3 million (2025), whereas its average is -$53.9 million.
  • In the last 5 years, Rhythm Pharmaceuticals' EBT soared by 292.47% in 2021 and then tumbled by 179.89% in 2022.
  • Rhythm Pharmaceuticals' EBT (Quarterly) stood at -$50.9 million in 2021, then increased by 16.44% to -$42.5 million in 2022, then increased by 2.49% to -$41.4 million in 2023, then dropped by 4.69% to -$43.4 million in 2024, then decreased by 20.03% to -$52.8 million in 2025.
  • Its EBT stands at -$52.8 million for Q3 2025, versus -$46.3 million for Q2 2025 and -$49.4 million for Q1 2025.